Background: Body weight may affect pharmacokinetic parameters in various ways and may therefore have a significant impact on the serum concentration of a drug at a given dose. Although patients with major depressive disorder frequently show an elevated body mass index, studies investigating the relation between body weight and serum concentration of antidepressants are lacking. This study should help to clarify the influence of body weight on the serum levels of the antidepressants amitriptyline (AMI), clomipramine (CLO), doxepine (DOX), escitalopram (ESC), and venlafaxine (VEN) in a naturalistic clinical setting.
Methods: Therapeutic drug monitoring analyses obtained in the psychiatric university hospital of Wuerzburg from patients treated with AMI (n = 171), CLO (n = 94), DOX (n = 133), ESC (n = 19), and VEN (n = 24) were retrospectively assessed. The influence of body weight on dose-corrected serum concentrations was evaluated by Spearman-Rho correlations and by comparing dose-corrected serum levels in patients with low and high body weight (first versus fourth quartile). The serum concentrations were determined by high-performance liquid chromatography methods in the therapeutic drug monitoring laboratory of the psychiatric university hospital of Wuerzburg.
Results: Dose-corrected serum concentrations did not significantly correlate with body weight in patients treated with AMI, CLO, DOX, ESC, or VEN. There was no significant difference in the dose-corrected serum concentrations of AMI, CLO, and DOX between patients of the first and fourth quartiles of body weight. The latter evaluation was not performed for ESC and VEN because of too small samples.
Conclusions: Against the intuitive presumption of a weight dependency of dose-corrected serum concentrations, the findings suggest that there is no relevant influence of body weight on the dose-corrected serum level of several widely used antidepressants even if extreme subgroups of patients with low and high body weights are considered.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/FTD.0b013e318237b0fa | DOI Listing |
J Biochem Mol Toxicol
January 2025
Medical Experiment Center, Shaanxi University of Chinese Medicine, Xianyang, China.
Bisphenol A (BPA), an environmental endocrine disrupting chemical, is one of the most widely used chemicals in the world and is widely distributed in the external environment, specifically in food, water, dust, and soil. BPA exposure is associated with abnormal cognitive behaviors. However, the underlying mechanism remains unclear.
View Article and Find Full Text PDFClin Oral Investig
January 2025
Department of Behavioral and Community Dentistry, Institute of Odontology, Sahlgrenska Academy, University of Gothenburg, P.O. Box 450, Gothenburg, SE-40530, Sweden.
Objective: To investigate if changes in body mass index (BMI) result in changes of the mandibular trabecular bone structure.
Materials And Methods: Females (18-35 years at baseline, mean BMI 42,3) were followed from before (n = 117) until two years (n = 66) after obesity treatment (medical or surgical). The mandibular bone trabeculation was classified as sparse, dense, or mixed on intraoral radiographs (Lindh's index).
Eat Weight Disord
January 2025
Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Orv Hetil
January 2025
1 Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház-Rendelőintézet, Általános-Mellkassebészeti Osztály Szolnok Magyarország.
Cell Mol Biol (Noisy-le-grand)
January 2025
Veterinary Medicine College, University Of Kerbala, Kerbala, Iraq.
Vitamin E is a well-known antioxidant and is frequently used as an adjunct treatment in cancer therapy. Busulfan is a commonly used drug for cancer treatment. In this study, twenty-eight male rats, ten weeks old and weighing between 250 and 300 grams, were divided into four groups.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!